Lapatinib

Recent Results in Cancer Research

Volumn 201, Issue , 2014, Pages 125-143

  Nolting, Minna ^a   Schneider Merck, Tanja ^a   Trepel, Martin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INHIBITION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROESOPHAGEAL CANCER; HEART FAILURE; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SECONDARY HEALTH CARE; ANIMAL; BREAST TUMOR; DRUG ANTAGONISM; FEMALE; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84906927270     PISSN: 00800015     EISSN: 21976767     Source Type: Book Series    
DOI: 10.1007/978-3-642-54490-3_7     Document Type: Article

References (75)

1. Bang Y (2012) A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study. J Clin Oncol 30(34):11
2. Bang YJ, Van Cutsem E et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (9742):687–697
3. Baselga J, Bradbury I et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379(9816):633–640
4. Bence AK, Anderson EB et al (2005) Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs 23(1):39–49
5. Blackwell K, Kaplan E et al (2004) A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 22(3006)
6. Blackwell KL, Burstein HJ et al (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28(7):1124–1130
7. Boku N (2013) HER2-positive gastric cancer. Gastric Cancer (Epub ahead of print)
8. Burris HA 3rd (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9(Suppl 3):10–15
9. Burris HA 3rd, Hurwitz HI et al (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23(23):5305–5313
10. Cameron D, Casey M et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112(3):533–543
11. Cameron D, Casey M et al (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15(9):924–934
12. Chen C, Yang JM et al (2013) Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. Arch Med Res 44(5):380–389
13. Chu QS, Schwartz G et al (2007) Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. J Clin Oncol 25(24): 3753–3758
14. Chu QS, Cianfrocca ME et al (2008) A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res 14(14): 4484–4490
15. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7(7):505–516
16. Clayton AJ, Danson S et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91(4):639–643
17. Danielsen AJ, Maihle NJ (2002) The EGF/ErbB receptor family and apoptosis. Growth Factors 20(1):1–15
18. Di Leo A, Gomez HL et al (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26(34):5544–5552
19. Esteva FJ, Franco SX et al (2013) An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. Oncologist 18(6):661–666
20. Frassoldati A, Guarneri V et al (2008) Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). Clin Breast Cancer 8(1):97–100
21. Gelmon KA, Boyle F et al. (2012) Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 30: 812. (ASCO Annual Meeting Abstracts) (LBA671)
22. Geyer CE, Forster J et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743
23. GlaxoSmithKline (2007) Lapatinib (package insert)
24. GlaxoSmithKline (2013) Lapatinib plus capecitabine versus trastuzumab plus capecitabine in ErbB2 (HER2) positive metastatic breast cancer. From http://clinicaltrials.gov/show/NCT00820222
25. Gomez HL, Doval DC et al (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26(18):2999–3005
26. Goss PE, Smith IE et al (2012) Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 14(1):88–96
27. Graus-Porta D, Beerli RR et al (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16(7):1647–1655
28. Gril B, Palmieri D et al (2008) Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100(15):1092–1103
29. Guan Z, Xu B et al (2013) Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol 31(16):1947–1953
30. Guarneri V, Frassoldati A et al (2012) Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Onco l30(16):1989–1995
31. Hecht J R, Y J Bang et al (2013) Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. J Clin Oncol 31(18):abstract-LBA4001 [ASCO Annual Meeting Proceedings (Post-Meeting Edition)]
32. Hong L, Han Y et al (2013) Prognostic value of epidermal growth factor receptor in patients with gastric cancer: a meta-analysis. Gene 529(1):69–72
33. Horn L, Lovly C (2012) Update on HER1-3 in advanced non-small-cell lung cancer. J Thorac Oncol 7(16):S369–S371
34. Iqbal S, Goldman B et al. (2007). S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients with advanced or metastatic gastric cancer. J Clin Oncol 25(18):4621 (ASCO Annual Meeting Proceedings (Post-Meeting Edition))
35. Johnston S, Pippen J Jr et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27(33):5538–5546
36. Kim JW, Kim HP et al (2008) The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 272(2):296–306
37. Klapper LN, Kirschbaum MH et al (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77:25–79
38. Kohler J, Schuler M (2013) Afatinib, Erlotinib and Gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie 36(9):510–518
39. Konecny GE, Pegram MD et al (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66(3):1630–1639
40. Lin NU, Winer EP (2004) New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res 6(5):204–210
41. Lin NU, Carey LA et al (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26(12): 1993–1999
42. Lin NU, Dieras V et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15(4):1452–1459
43. Lin NU, Eierman W et al (2011) Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 105(3):613–620
44. Medina PJ, Goodin S (2008) Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30(8):1426–1447
45. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21(14):2787–2799
46. Moy B, Goss PE (2007) Lapatinib-associated toxicity and practical management recommendations. Oncologist 12(7):756–765
47. Nahleh ZA (2008) Molecularly targeted therapy in breast cancer: the new generation. Recent Patents Anticancer Drug Discov 3(2):100–104
48. Nahta R, Hortobagyi GN et al (2003) Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 8(1):5–17
49. Nelson MH, Dolder CR (2006) Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 40(2):261–269
50. Okano J, Gaslightwala I et al (2000) Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem 275(40):30934–30942
51. Olayioye MA, Neve RM et al (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19(13):3159–3167
52. Perez EA, Koehler M et al (2008) Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83(6):679–686
53. Piccart-Gebhart MJ, Procter M et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672
54. Prenzel N, Fischer OM et al (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8(1):11–31
55. Rahman A, Pazdur R et al (2007) The value meal: effect of food on lapatinib bioavailability. J Clin Oncol 25(33):5333–5335
56. Rana P, Sridhar SS (2012) Efficacy and tolerability of lapatinib in the management of breast cancer. Breast Cancer (Auckl) 6:67–77
57. Rapidis AD, Vermorken JB et al (2008) Targeted therapies in head and neck cancer: past, present and future. Rev Recent Clin Trials 3(3):156–166
58. Ratain MJ, Cohen EE (2007) The value meal: how to save $1,700 per month or more on lapatinib. J Clin Oncol 25(23):3397–3398
59. Rivera F, Vega-Villegas ME et al (2008) Cetuximab, its clinical use and future perspectives. Anticancer Drugs 19(2):99–113
60. Robidoux A, Tang G et al (2012) Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. J Clin Oncol 30:812 (ASCO Annual Meeting Abstract LBA506)
61. Romond EH, Perez EA et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684
62. Scaltriti M, Verma C et al (2009) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28(6):803–814
63. Singh BN, Malhotra BK (2004) Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet 43(15):1127–1156
64. Sliwkowski MX (2003) Ready to partner. Nat Struct Biol 10(3):158–159
65. Stebbing J, Copson E et al (2000) Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat Rev 26(4):287–290
66. Stern DF (2000) Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res 2(3):176–183
67. Stern HM (2012) Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med 4(127):127rv2
68. Tomasello G, de Azambuja E et al (2008) Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 8(12):1883–1890
69. Untch M, Loibl S et al (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13(2):135–144
70. Wainberg ZA, Anghel A et al (2010) Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 16(5):1509–1519
71. Witton CJ, Reeves JR et al (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200(3):290–297
72. Wood ER, Truesdale AT et al (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor offrate, and receptor activity in tumor cells. Cancer Res 64(18):6652–6659
73. Xia W, Liu LH et al (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23(3):646–653
74. Xia W, Gerard CM et al (2005) Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24(41):6213–6221
75. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–137